Our therapies

SafeR™

SafeR allows for intelligent management of AV conduction, significantly reducing unnecessary RV pacing in all pacemaker patients, including AV block patients.1–8

AutoMRI™

AutoMRI mode is the world’s first pacemaker technology capable of detecting an MRI field and automatically switching to asynchronous mode.

SAM™

Proactive management of comorbidities. Early detection, long-term risk reduction. 1–6

Parad+™

World's first dual-chamber discrimination algorithm.

Dual Sensor™

Twin trace is designed to physiologically modulate the heart rhythm by combining Accelerometer and Minute Ventilation sensors.

SonR™ CRT Optimization

SonR™ measures real-time LV contractilty1 to optimize AV & VV delays.

BTO™

Brady Tachy OverlapTM – BTOTM

96% specificity in slow VT zone.9

A proof of Parad+TM discrimination performance.

Multipoint Pacing™

Capture a broader area of LV,10 reduce persistent mechanical dyssynchrony11 and improve hemodynamics.12

  1. Stockburger M, et al. Long-term clinical effects of ventricular pacing reduction with a changeover mode to minimize ventricular pacing in general population (ANSWER study). European Heart Journal. 2015;36:151–57.
  2. Andersen HR, et al. Long-term follow-up of patients from a randomized trial of atrial versus ventricular pacing for sick-sinus syndrome. Lancet. 1997;350:1210–16.
  3. Skanes AC, et al. Progression to chronic atrial fibrillation after pacing: The Canadian Trial Of Physiologic Pacing (CTOPP). J Am Coll Cardiol. 2001;38:167–72.
  4. Nielsen J, et al. A randomized comparison of atrial and dual chamber pacing in 177 consecutive patients with sick sinus syndrome. J Am Coll Cardiol. 2003; 42: 614–23.
  5. Sweeney M, et al. Adverse effect of ventricular pacing on heart failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction. Circulation. 2003;107:2932–37.
  6. Wilkoff BL, et al. Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID trial). JAMA. 2002;288:3115–23.
  7. Stockburger M, et al. Safety and efficiency of ventricular pacing prevention with an AAI-DDD changeover mode in patients with sinus node disease or atrioventricular block: impact on battery longevity-a substudy of the ANSWER trial. Europace 2016;18:739–46.
  8. Benkemoun H, et al. Optimizing pacemaker longevity with pacing mode and settings programming: results from a pacemaker multicenter registry. Pacing Clin Electrophysiol 2012;35:403–08.
  9. Sadoul N, et al. Incidence and clinical relevance of slow ventricular tachycardia in implantable cardioverter-defibrillator recipients: an international multicenter prospective study. Circulation. 2005;16;112:946–53. 
  10. Menardi E, et al. Characterization of ventricular activation pattern and acute hemodynamics during multipoint left ventricular pacing. Heart Rhythm. 2015;12:1762–69
  11. Rinaldi CA, et al. Acute effects of multisite left ventricular pacing on mechanical dyssynchrony in patients receiving cardiac resynchronization therapy. J Card Fail. 2013;19:731–38.
  12. Thibault B, et al. Acute haemodynamic comparison of multisite and biventricular pacing with a quadripolar left ventricular lead. Europace. 2013;15:984–91.
Exemplary message

By continuing to browse this website you confirm that you are a healthcare professional.